

**Preferred CSF**  
**Effective July 7, 2019**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	These medications have been designated specialty and must be filled at a contracted specialty pharmacy when filled via that pharmacy benefit.		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, and the member has no exclusions to the prescribed therapy.

**Leukine, Neupogen, Nivestym, Zarxio**

- Myelosuppressive chemotherapy recipients with non-myeloid malignancies: To decrease the incidence of infection (neutropenic fever) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of severe neutropenia with fever
- Acute myeloid leukemia (AML) following induction or consolidation chemotherapy: To reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy in adults with AML
- Bone marrow transplantation: To reduce the duration of neutropenia and neutropenia-related events (e.g., neutropenic fever) in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by marrow transplantation
- Peripheral blood progenitor (PBPC) cell collection and therapy: Mobilization of autologous hematopoietic progenitor cells into the peripheral blood for apheresis collection
- Severe chronic neutropenia: Long-term administration to reduce the incidence and duration of neutropenic complications (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic, or idiopathic neutropenia

**Granix**

- Myelosuppressive chemotherapy recipients with non-myeloid malignancies: To decrease the duration of severe neutropenia in adult and pediatric patients ≥1 month of age with non-myeloid



malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of neutropenic fever

### **Neupogen only**

- Hematopoietic radiation injury syndrome, acute: To increase survival in patients acutely exposed to myelosuppressive doses of radiation

### **Compendial Uses For (Neupogen, Granix, Zarxio, Nivestym)**

1. Treatment of chemotherapy-induced febrile neutropenia in patients with non-myeloid malignancies
2. Treatment of anemia in patients with myelodysplastic syndromes (MDS)
3. Treatment of neutropenia in patients with MDS
4. Following chemotherapy for acute lymphocytic leukemia (ALL)
5. Stem cell transplantation-related indications
6. Agranulocytosis
7. Aplastic anemia
8. Neutropenia related to HIV/AIDS

### **Compendial Uses for Leukine**

1. Neuroblastoma in high-risk pediatric patients
2. Primary prophylaxis of neutropenia in patients receiving chemotherapy (outside of transplant and AML) or who are at high risk for neutropenic fever.

## **Coverage Guidelines**

### **Zarxio**

- Authorization may be granted for Zarxio for members being treated for any of the FDA indications or compendial uses.

### **Granix, Neupogen, Nivestym**

- Authorization may be granted for Granix, Neupogen, or Nivestym when prescriber has submitted documentation of previous treatment failure, intolerance or a contraindication with Zarxio  
**OR**
- The prescriber has submitted clinical rationale why Zarxio is not an appropriate therapy.

### **Granix, Neupogen**

- Authorization may be granted for Granix or Neupogen when the requested doses are less than 180mcg.

### **Leukine**

- Authorization may be granted for Leukine when member has a documented inadequate response or an intolerable adverse effect to Zarxio.

## **Limitations**

Approvals will be granted for 6 months

## **References**



1. Granix (tbo-filgrastim) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; March 2019.
2. Leukine (sargramostim) [prescribing information]. Lexington, MA: Partner Therapeutics; May 2018.
3. Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; June 2018
4. Nivestym (filgrastim-aafi) [prescribing information]. Lake Forest, IL: Hospira Inc; July 2018
5. Zarxio (filgrastim-sndz) [prescribing information]. Princeton, NJ: Sandoz Inc; April 2018

### **Review History**

06/19/19 – Updated (Added Zarxio as preferred agent, Neulasta is on separate criteria, added Nivestym as new biosimilar to CSF criteria)

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.